Mphatso Dennis Phiri, Matthew Cairns, Issaka Zongo, Frederic Nikiema, Modibo Diarra, Rakiswendé Serge Yerbanga, Amadou Barry, Amadou Tapily, Samba Coumare, Ismaila Thera, Irene Kuepfer, Paul Milligan, Halidou Tinto, Alassane Dicko, Jean Bosco Ouédraogo, Brian Greenwood, Daniel Chandramohan, Issaka Sagara
BACKGROUND: Mass drug administration (MDA) with azithromycin (AZ) is being considered as a strategy to promote child survival in sub-Saharan Africa, but the mechanism by which AZ reduces mortality is unclear. To better understand the nature and extent of protection provided by AZ, we explored the profile of protection by time since administration, using data from a household-randomised, placebo-controlled trial in Burkina Faso and Mali. METHODS: Between 2014 and 2016, 30,977 children aged 3-59 months received seasonal malaria chemoprevention (SMC) with sulphadoxine-pyrimethamine plus amodiaquine and either AZ or placebo monthly, on four occasions each year...
January 8, 2021: Clinical Infectious Diseases